Beam Therapeutics Inc [BEAM] stock prices are up 2.43% to $21.54 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BEAM shares have gain 10.01% over the last week, with a monthly amount glided 28.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on March 28, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $42 for it. Previously, Scotiabank upgraded its rating to Sector Outperform on March 10, 2025, and kept the price target unchanged to $40. On January 29, 2025, upgrade upgraded it’s rating to Overweight. Leerink Partners upgraded its rating to a Outperform and increased its price target to $39 on November 06, 2024. Scotiabank initiated its recommendation with a Sector Outperform. H.C. Wainwright started tracking with a Buy rating for this stock on July 23, 2024, and assigned it a price target of $80. In a note dated January 29, 2024, JP Morgan upgraded an Overweight rating on this stock and boosted its target price from $38 to $40.
The stock price of Beam Therapeutics Inc [BEAM] has been fluctuating between $13.52 and $35.25 over the past year. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $21.54 at the most recent close of the market. An investor can expect a potential return of 85.7% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
The Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 63.58M for trailing twelve months, representing a surge of 0.81%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -6.77%, Pretax Profit Margin comes in at -6.09%, and Net Profit Margin reading is -6.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.44 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.01 points at the first support level, and at 20.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.91, and for the 2nd resistance point, it is at 22.28.
Ratios To Look Out For
It’s worth pointing out that Beam Therapeutics Inc [NASDAQ:BEAM]’s Current Ratio is 8.81. As well, the Quick Ratio is 8.81, while the Cash Ratio is 3.73. Considering the valuation of this stock, the price to sales ratio is 34.07, the price to book ratio is 1.93.
Transactions by insiders
Recent insider trading involved Simon Amy, Chief Medical Officer, that happened on Jul 03 ’25 when 876.0 shares were sold. Chief Medical Officer, Simon Amy completed a deal on Jul 01 ’25 to sell 374.0 shares. Meanwhile, Chief Legal Officer Bellon Christine sold 5674.0 shares on Apr 01 ’25.
